Group 1 - The company plans to globally offer 33.44 million shares, with 3.34 million shares available in Hong Kong and 30.10 million shares for international offering [1] - The subscription period is from July 31 to August 5, with a maximum offer price of HKD 15.50 per share and an entry fee of approximately HKD 3,131.26 for 200 shares [1] - The total expected fundraising amount is HKD 475 million, with a net amount of HKD 421 million allocated for core product development, vaccine registration, production capacity enhancement, working capital, and technology platform upgrades [1] Group 2 - The company is a China-based vaccine firm focused on innovative vaccines and the application of new technologies in traditional vaccine development, manufacturing, and commercialization [2] - The product pipeline includes two core products: a quadrivalent influenza virus subunit vaccine and an in-development freeze-dried human rabies vaccine, along with 11 other vaccines in research [2] - The company reported net losses of HKD 425 million for 2023, HKD 259 million for 2024, and HKD 87.31 million for the first quarter of 2025 [2]

Group 1 - The company plans to globally offer 33.44 million shares, with 3.34 million shares available in Hong Kong and 30.10 million shares for international sale [1] - The subscription period is from July 31 to August 5, with a maximum offer price of HKD 15.50 per share and an entry fee of approximately HKD 3,131.26 for 200 shares [1] - The total expected fundraising amount is HKD 475 million, with a net amount of HKD 421 million allocated for core product development, vaccine research, production capacity enhancement, working capital, and technology platform upgrades [1] Group 2 - The company is a China-based vaccine firm focused on innovative vaccines and the commercialization of traditional vaccines using new technologies [2] - The product pipeline includes two core products: a quadrivalent influenza virus subunit vaccine and a developing freeze-dried human rabies vaccine, along with 11 other vaccines in development [2] - The net profits for the fiscal years 2023, 2024, and the first quarter of 2025 are projected to be -425 million, -259 million, and -87.31 million respectively [2]

Group 1 - The company, Zhonghui Biotech-B (02627), plans to conduct an initial public offering (IPO) from July 31 to August 5, 2025, with a global offering of 33.44 million H-shares, where 10% will be offered in Hong Kong and 90% internationally [1] - The offering price per share is set between HKD 12.9 and HKD 15.5, with trading expected to commence on August 8, 2025 [1] - The company focuses on the research, development, manufacturing, and commercialization of innovative vaccines and traditional vaccines using new technologies, aiming to replace traditional and imported vaccines in China and expand its competitive advantage internationally [1] Group 2 - The cornerstone investors, including Jiaxing Xinyang and Huatai Capital Investment, have agreed to subscribe for shares worth approximately USD 13 million, with an estimated subscription of 7.1136 million H-shares at a midpoint offering price of HKD 14.20 per share [2] - This subscription represents about 21.3% of the total shares offered in the global offering, assuming no exercise of the over-allotment option [2] - The estimated net proceeds from the global offering, after deducting underwriting fees and expenses, is approximately HKD 421 million [2] Group 3 - The company plans to allocate approximately 63.6% of the net proceeds from the global offering to the development and registration of its core products, with specific allocations for ongoing research and overseas registration of the quadrivalent influenza virus subunit vaccine and the Phase III clinical trial of the freeze-dried rabies vaccine [3] - About 18.1% will be used for the development and registration of other pipeline vaccines, while 8.4% will enhance production and commercialization capabilities [3] - Additionally, 4.9% will be allocated for the development and operation of various technological platforms, and 5.0% will be used for working capital and general corporate purposes [3]

公司、联席保荐人及整体协调人已与基石投资者(即嘉兴鑫扬及华泰资本投资(与华泰背对背总回报掉期 及华泰客户总回报掉期有关))订立基石投资协议，基石投资者同意认购可按发售价购买有关数目的发售 股份，认购总金额为1300万美元(约为1.02亿港元)。假设发售价为每股发售股份14.20港元(即本招股章程 所载指示性发售价范围的中位数)，基石投资者将予认购的发售股份总数将为711.36万股H股。 假设发售价为每股发售股份14.20港元(即本招股章程所载指示性发售价范围的中位数)及假设发售量调整 权未获行使，公司估计将获得所得款项净额约4.205亿港元。公司计划将全球发售所得款项净额用于以 下用途：(i)约63.6%将分配至公司的核心产品的开发及国内外注册，其中：(a)约32.4%将用于公司的四 价流感病毒亚单位疫苗的持续研发及海外市场注册；(b)约31.2%将用于公司的在研冻乾人用狂犬病疫苗 的III期临床试验及注册，公司预计于2025年第三季度启动该试验；(ii)约18.1%将用于公司的其他在研疫 苗的开发和注册；(iii)约8.4%将分配至提升公司的生产及商业化能力；(iv)约4.9%将分配至公司的技术 平台(包括 ...

格隆汇7月31日丨中慧生物-B(02627.HK)发布公告，公司拟全球发售3344.26万股H股(视发售量调整权行 使与否而定)，中国香港发售股份334.44万股，国际发售股份3009.82万股；2025年7月31日至8月5日招 股，预期定价日为8月6日；发售价将为每股发售股份12.90-15.50港元，每手买卖单位为200股，中信证 券及招银国际为联席保荐人；预期股份将于2025年8月8日开始在联交所买卖。 ...

江蘇中慧元通生物科技股份有限公司 Ab&B Bio-Tech CO., LTD. JS 全球發售 聯席保薦人、整體協調人、聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人 聯席賬簿管理人兼聯席牽頭經辦人 Ab&B Bio-Tech CO., LTD. JS 江蘇中慧元通生物科技股份有限公司 重要提示 （於中華人民共和國成立的股份有限公司） 股份代號 : 2 6 2 7 重要提示：閣下如對本招股章程的任何內容有任何疑問，應尋求獨立專業意見。 Ab&B Bio-Tech CO., LTD. JS 江蘇中慧元通生物科技股份有限公司 （於中華人民共和國成立的股份有限公司） 全球發售 全球發售項下的發售股份數目 33,442,600股H股（視發售量調整權 行使與否而定） 香港發售股份數目 3,344,400股H股（可予重新分配） 國際發售股份數目 30,098,200股H股（可予重新分配及 視發售量調整權行使與否而定） 最高發售價 每股H股15.50港元，另加1.0%經紀 佣金、0.0027%證監會交易徵費、 0.00565%聯交所交易費及 0.00015%會財局交易徵費（須於申請 時以港元繳足，多繳股款可予退還） 面值 ...

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表聲明，並明確表示概不 會就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 本公告不得直接或間接於或向美國（包括其領土及屬地、美國任何州以及哥倫比亞特區）發佈、 刊發或派發。本公告並不構成或組成在美國境內或於任何其他司法權區購買或認購發售股份的 任何要約或招攬的一部分。發售股份並無亦不會根據《1933年美國證券法》（經不時修訂）（「美 國證券法」）或美國任何州或其他司法權區的證券法登記。發售股份不得在美國境內提呈發售、 出售、質押或以其他方式轉讓，除非已根據美國證券法及《1940年美國投資公司法》（經修訂） （「美國投資公司法」）的登記規定獲豁免，並已符合任何州的適用證券法。發售股份根據美國證 券法S規例在美國境外向非美籍人士投資者或並非為美籍人士或為其利益進行收購的投資者提 呈發售及出售。發售股份不會在美國公開發售。 本公告僅作說明用途，並不構成收購、購買或認購證券的邀請或要約。本公告並非招股章程。 潛在投資者於決定是否投資所提 ...